

Generalized Myasthenia Gravis (gMG) Symptom Assessment

The **Myasthenia Gravis Activities of Daily Living (MG-ADL)** scale assesses the impact of gMG on daily functions by measuring 8 signs or symptoms that are commonly affected in gMG. Each item is measured on a 4-point scale, where a score of 0 represents normal function and a score of 3 represents the loss of ability to perform that function. Total scores range from 0 to 24 points, with a higher score showing more severe gMG.

Track your symptoms regularly. If you track them weekly, try to do it at the same time each week for consistency.*

Date: _____ **Time:** _____ AM PM **Week:** _____

Grade	0	1	2	3	Score (0, 1, 2, or 3)
1. Talking	Normal	Intermittent slurring or nasal speech	Constant slurring or nasal, but can be understood	Difficult to understand speech	+
2. Chewing	Normal	Fatigue with solid food	Fatigue with soft food	Gastric tube	+
3. Swallowing	Normal	Rare episode of choking	Frequent choking necessitating changes in diet	Gastric tube	+
4. Breathing	Normal	Shortness of breath with exertion	Shortness of breath at rest	Ventilator dependence	+
5. Impairment of ability to brush teeth or comb hair	None	Extra effort, but no rest periods needed	Rest periods needed	Cannot do one of these functions	+
6. Impairment of ability to arise from a chair	None	Mild, sometimes uses arms	Moderate, always uses arms	Severe, requires assistance	+
7. Double vision	None	Occurs, but not daily	Daily, but not constant	Constant	+
8. Eyelid droop	None	Occurs, but not daily	Daily, but not constant	Constant	+
MG-ADL score total =					
Add lines 1-8					

This information has been provided for educational purposes only and is not meant to be a substitute for professional medical advice. Patients should not use this information for diagnosing a health condition. Patients should always consult a healthcare professional for medical advice or information about diagnosis and treatment.

Source: Wolfe GI, et al. *Neurology*. 1999;52(7):1487-1489.

*The MG-ADL was assessed weekly for 8 weeks after the initiation of each cycle and then every 2 weeks up to 26 weeks.

➔ My other gMG symptoms

➔ Questions for my neurologist

➔ Other notes

Remember to let your neurologist know if there are any changes to your MG-ADL score or if you have questions about VYVGART Hytrulo for subcutaneous injection or VYVGART for intravenous (IV) infusion

What is VYVGART® (efgartigimod alfa-fcab) for intravenous (IV) infusion and what is VYVGART HYTRULO® (efgartigimod alfa and hyaluronidase-qvfc) for subcutaneous injection?

VYVGART and VYVGART HYTRULO are both prescription medicines used to treat adults with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody positive.

It is not known if VYVGART or VYVGART HYTRULO is safe and effective in children.

SELECT IMPORTANT SAFETY INFORMATION

Do not take VYVGART if you are allergic to efgartigimod alfa or any of the ingredients in VYVGART. Do not take VYVGART HYTRULO if you are allergic to efgartigimod alfa, hyaluronidase, or any of the ingredients in VYVGART HYTRULO. VYVGART or VYVGART HYTRULO can cause serious allergic reactions and a decrease in blood pressure leading to fainting.

Please see Important Safety Information on last page. Please see full [Prescribing and Patient Information for VYVGART HYTRULO for subcutaneous injection](#) and full [Prescribing Information](#) for VYVGART for IV infusion.

My VYVGART Path is a patient support program that provides personalized assistance throughout your treatment journey

There are 2 options to enroll:

1

Complete the enrollment form online to self-enroll

2

Speak with your doctor and ask to be enrolled

Once you're enrolled, a Nurse Case Manager is ready to help you. Give them a call at **1-833-MY-PATH-1** (1-833-697-2841).

Looking for a different way to track symptoms?

For personalized support WHEREVER YOU GO, download the My VYVGART App by Medisafe.

- ➔ Track symptoms
- ➔ Set appointment reminders
- ➔ Explore education and resources



Scan to download from your device's app store

Follow the prompts within the app and select VYVGART as your medication to access the My VYVGART App. Ask your Nurse Case Manager for a code to unlock app features.



IMPORTANT SAFETY INFORMATION

Do not take VYVGART if you are allergic to efgartigimod alfa or any of the ingredients in VYVGART. Do not take VYVGART HYTRULO if you are allergic to efgartigimod alfa, hyaluronidase, or any of the ingredients in VYVGART HYTRULO. VYVGART or VYVGART HYTRULO can cause serious allergic reactions and a decrease in blood pressure leading to fainting.

Before taking VYVGART or VYVGART HYTRULO, tell your healthcare provider about all of your medical conditions, including if you:

- have an infection or fever.
- have recently received or are scheduled to receive any vaccinations.
- have any history of allergic reactions.
- have kidney (renal) problems.
- are pregnant or plan to become pregnant. It is not known whether VYVGART or VYVGART HYTRULO will harm your unborn baby.
 - Pregnancy Exposure Registry. There is a pregnancy exposure registry for women who use VYVGART or VYVGART HYTRULO during pregnancy. The purpose of this registry is to collect information about your health and your baby. Your healthcare provider can enroll you in this registry. You may also enroll yourself or get more information about the registry by calling 1-855-272-6524 or going to VYVGARTPregnancy.com
- are breastfeeding or plan to breastfeed. It is not known if VYVGART or VYVGART HYTRULO passes into your breast milk.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

VYVGART or VYVGART HYTRULO can cause side effects which can be serious, including:

- **Infection.** VYVGART or VYVGART HYTRULO may increase the risk of infection. If you have an active infection, your healthcare provider should delay your treatment with VYVGART or VYVGART HYTRULO until your infection is gone. Tell your healthcare provider right away if you get any of the following signs and symptoms of an infection:
 - fever
 - chills
 - frequent and painful urination
 - cough
 - pain and blockage of nasal passages
 - wheezing
 - shortness of breath
 - sore throat
 - excess phlegm
 - nasal discharge
- **Allergic reactions (hypersensitivity reactions).** VYVGART or VYVGART HYTRULO can cause allergic reactions that can be severe. These reactions can happen during, shortly after, or weeks after your

VYVGART infusion or VYVGART HYTRULO injection. Tell your healthcare provider or get emergency help right away if you have any of the following symptoms of an allergic reaction with VYVGART or VYVGART HYTRULO:

- rash
- swelling of the face, lips, throat, or tongue
- shortness of breath
- trouble breathing
- low blood pressure
- fainting

An additional symptom of an allergic reaction with VYVGART HYTRULO can include hives.

- **Infusion or injection-related reactions.** VYVGART can cause infusion-related reactions. VYVGART HYTRULO can cause infusion or injection-related reactions. These reactions can happen during or shortly after your VYVGART infusion or VYVGART HYTRULO injection. Tell your healthcare provider if you have any of the following symptoms of an infusion or injection-related reaction:

- high blood pressure
- chills
- shivering
- chest, stomach, or back pain

The most common side effects of VYVGART or VYVGART HYTRULO include respiratory tract infection, headache, and urinary tract infection. An additional common side effect with VYVGART HYTRULO includes injection site reactions.

These are not all the possible side effects of VYVGART or VYVGART HYTRULO. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

What is VYVGART® (efgartigimod alfa-fcab) for intravenous (IV) infusion and what is VYVGART HYTRULO® (efgartigimod alfa and hyaluronidase-qvfc) for subcutaneous injection?

VYVGART and VYVGART HYTRULO are both prescription medicines used to treat adults with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody positive.

It is not known if VYVGART or VYVGART HYTRULO is safe and effective in children.

Please see full [Prescribing and Patient Information for VYVGART HYTRULO for subcutaneous injection](#) and full [Prescribing Information for VYVGART for IV infusion](#).**Dosage forms and strengths:**

VYVGART Hytrulo is available as a single-dose subcutaneous injection containing: 200 mg/mL of efgartigimod alfa and 2,000 U/mL of hyaluronidase per prefilled syringe, or 180 mg/mL of efgartigimod alfa and 2,000 U/mL of hyaluronidase per vial. VYVGART is available as a single-dose injection for intravenous use containing 400 mg/20 mL of efgartigimod alfa-fcab per vial.